Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Dec 10, 2024, 07:30 ET Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…
Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology NEWS PROVIDED BY Alphyn Biologics Nov 01, 2024, 07:30 ET Paper highlights Zabalafin Hydrogel’s potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/…
International Society of Atopic Dermatitis Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin NEWS PROVIDED BY Alphyn Biologics October 26, 2024, 19:30 ET N432_Neal-KOLLER_Itch-Reduction-and-Quality-of-Life-Improvement-in-AD-for-First-Human-Use-of-Zabalfin CONTACTS Corporate: Neal Koller [email protected] (410) 690-8687 Media: Susan Thomas [email protected] (619) 540-9195
2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics September 28, 2024, 19:30 ET CONTACTS Corporate: Neal Koller [email protected] (410) 690-8687 Media: Susan Thomas [email protected] (619) 540-9195
Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 NEWS PROVIDED BY Alphyn Biologics Aug 27, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 27, 2024 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that data from its Phase 2a human clinical…
Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics Aug 21, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 21, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that it has received a notice of claims allowance from the U.S. Patent and Trademark…
Society for Pediatric Dermatology Poster Presentation: First-in-Human Phase 2 Trial of Zabalafin Hydrogel (AB-101a) – Itch and Quality of Life Pediatric Results NEWS PROVIDED BY Alphyn Biologics July 8, 2024, 19:30 ET CONTACTS Corporate: Neal Koller [email protected] (410) 690-8687 Media: Susan Thomas [email protected] (619) 540-9195
Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 07, 2024, 07:30 ET All endpoints met Significant improvements in itch and quality of life Significant control of staph bacteria-associated and other AD flares Clearance of infected AD skin Significant improvements in inflammation ANNAPOLIS,…
Masters of Pediatric Dermatology Symposium Poster Presentation: First in Human Phase 2 Trial of Zabalafin (AB-101) – Interim Results NEWS PROVIDED BY Alphyn Biologics February 8, 2023, 17:00 ET CONTACTS Corporate: Neal Koller [email protected] (410) 690-8687 Media: Susan Thomas [email protected] (619) 540-9195